← Search & browse all drugs
NERVOUS SYSTEM › PSYCHOLEPTICS › ANTIPSYCHOTICS › Other antipsychotics
cariprazine
N05AX15
Forms & Strengths
- Capsules: 1.5 mg, 3 mg, 4.5 mg, 6 mg
Adult Dosing
- Schizophrenia: Initial 1.5 mg once daily; target 1.5 to 6 mg once daily; max 6 mg/day.
- Bipolar mania: Initial 1.5 mg once daily; target 3 to 6 mg once daily; max 6 mg/day.
- Bipolar depression: Initial 1.5 mg once daily; target 1.5 to 3 mg once daily; max 3 mg/day.
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established.
Indications
- Treatment of schizophrenia in adults
- Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults
- Treatment of depressive episodes associated with bipolar disorder (bipolar depression) in adults
Mechanism of Action
- Atypical antipsychotic activity likely mediated through a combination of partial agonist activity at central dopamine D2 and serotonin 5-HT1A receptors, and antagonist activity at serotonin 5-HT2A receptors.
Contraindications
- Known hypersensitivity to cariprazine
- Concomitant use with strong CYP3A4 inhibitors or inducers
Adverse Reactions
- Extrapyramidal symptoms
- Akathisia
- Nausea
- Insomnia
- Somnolence
- Weight gain
- Dizziness
Drug Interactions
- Strong CYP3A4 inhibitors (e.g., ketoconazole): May increase cariprazine exposure; dose reduction recommended.
- Strong or moderate CYP3A4 inducers (e.g., carbamazepine, rifampin): May decrease cariprazine exposure; concomitant use not recommended.
- CNS depressants: May potentiate sedative effects and orthostatic hypotension.
Curated Content: Needs Vetting Before Put to Clinical Use